On June 23, WuXi Biologics rose 3.06% in regular trading, trading at HK$31.66/share, with turnover of HK$121 million.

On the news front, the company has been intensifying its share repurchase program. On June 22, the company spent approximately HK$49.24 million to buy back 1.6 million shares at prices between HK$30.66 and HK$31.14 per share. Earlier on June 18, it repurchased 3.26 million shares for approximately HK$99.74 million. Since the buyback authorization was approved at the shareholders meeting on June 10, the company has cumulatively repurchased over 11.5 million shares out of an authorized limit of approximately 412 million shares, signaling management confidence in the company's intrinsic value.

Meanwhile, the Life Sciences Tools and Services sector is broadly strengthening, with Insilico Medicine up 9.45%, XtalPi up 4.46%, WuXi XDC up 2.91%, GenScript Biotech up 2.36%, and WuXi AppTec up 1.28%. An industry-wide buyback wave among pharmaceutical companies continues to lift market sentiment, with sector valuation recovery expectations warming.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)